Europe Pharmaceutical Drugs Market to Reach US$ 219.9 Billion by the End of 2027 - Coherent Market Insights

News provided by

Mar 23, 2020, 10:47 ET

SEATTLE, March 23, 2020 /PRNewswire/ -- According to Coherent Market Insights, the Europe Pharmaceutical Drugs market was valued at US$ 152.1 billion in 2018, and is projected to exhibit a CAGR of 4.5% over the forecast period (2019–2027).

Key Trends and Analysis of the Europe Pharmaceutical Drugs Market:

Key trends in market are the rising prevalence of chronic and acute diseases, patient expiry of drugs, drug approvals & launch by key players in the market.

Increasing incidence and prevalence of chronic and acute wounds in individuals suffering from diseases such as diabetes is a leading factor for growth of the Europe Pharmaceutical Drugs market. For instance, according to Cancer Research UK, around 363,484 new cases of cancer were reported in the U.K during 2014 to 2016.

Request for Sample PDF copy @ https://www.coherentmarketinsights.com/insight/request-sample/3541

The growing healthcare expenditure is also expected to contribute to growth of the Europe Pharmaceutical Drugs market over the forecast period. For instance, according to the Office of National Statistics, the total healthcare expenditure in the U.K during 2017 was around 9.6% of the GDP (Gross Domestic Product)

Furthermore, key players operating in the market are focused on product launches to strengthen their market position and expand their product offerings in potential markets. For instance, in September 2019, Sanofi launched diabetes therapy Suliqua in the U.K. Suliqua is approved for treatment of type 2 diabetes mellitus.

Key Market Takeaways:

The Europe Pharmaceutical Drugs market is expected to exhibit a CAGR of 4.5% during the forecast period (2019–2027), owing to increasing incidence of diseases, new product launches and increasing healthcare expenditure. For instance, in March 2019, European Commission approved MabThera for the treatment of adults with moderate to severe pemphigus vulgaris (PV).
Key players in the market are focused on development of new products to expand their product portfolio, which is expected to propel the market growth over the forecast period. For instance, in January 2019, GlaxoSmithKline plc., a U.K. based company, announced acquisition of TESARO, Inc. for development of cancer therapy.

Key players operating in the Europe Pharmaceutical Drugs market include—

Allergan plc. , Novo Nordisk, Boehringer Ingelheim, Merck KGaA, GlaxoSmithKline Plc. , AstraZeneca Plc., Baxter AG, Novartis AG, F. Hoffmann-La Roche Ltd, Shire, and Sanofi.

Buy this Report Now @ https://www.coherentmarketinsights.com/insight/buy-now/3541

Market Segmentations:

Europe Pharmaceutical Drugs Market, By Drug Type:

Generic Drugs
Branded Drugs

Global Europe Pharmaceutical Drugs Market, By Product Type:

Prescription Drugs
Over-the-counter (OTC) Drugs

Global Europe Pharmaceutical Drugs Market, By Application:

Cardiovascular
Musculoskeletal
Oncology
Anti-infective
Metabolic Disorder
Central Nervous System
Genito-urinary
Gastrointestinal
Respiratory
Hematology
Dermatology
Ophthalmology
Others

Global Europe Pharmaceutical Drugs Market, By Distribution Channel:

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

Global Europe Pharmaceutical Drugs Market, By Country/Region:

U.K.
Germany
France
Italy
Spain
Russia
Netherlands
Poland
Switzerland
Sweden
Rest of Europe

Did not find what you were looking for? Here are some similar topics:

NORTH AMERICA SYNTHETIC OPIOIDS MARKET

Synthetic Opioids (CVIS) are opioid receptor agonists and act primarily on the brain and spinal cord and are used for pain relief. Most commonly prescribed synthetic opioids include, methadone, fentanyl and meperidine. Increasing prevalence of cancer is expected to boost growth of North America synthetic opioids market over the forecast period. Increasing adoption of expansion strategies from major market players through strategic investments, licensing agreements, and acquisitions for strengthening their market positioning is also anticipated to assist the growth of the market.

NEUROPATHIC PAIN MARKET

Neuropathic pain is a condition which involves pain caused due to damage or diseases affecting the nervous system. These conditions may include diseases such as diabetes causing diabetic neuropathy, chemotherapy induced neuropathic pain, and trigeminal neuralgia. Diabetic neuropathy is the damage caused to the nerve due to diabetes which often leads to pain and numbness in feet or lower legs.

LYSOSOMAL STORAGE DISEASES THERAPEUTICS MARKET

The deficiency of enzymes that causes a specific disease condition called lysosomal storage disease includes diseases such as Fabry Disease, Gaucher disease, lysosomal acid lipase deficiency, mucopolysaccharidosis, Hunter syndrome, and Pompe disease. Enzyme replacement therapy involves intravenous administration of enzymes in order to correct the deficiency of enzymes.

Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave.
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]

SOURCE Coherent Market Insights